Max joined Transpharmation Ltd in January 2014 as General Manager and Scientific Director of the Irish subsidiary Transpharmation Ireland Ltd, a Campus Company at the Trinity College Dublin where he is also an adjunct professor at the school of psychology. Dr. M. Bianchi has 16 years of research experience on neuropharmacology, neuronal cytoskeletal plasticity, and drug discovery. He worked with the former Psychiatry Centre of Excellence for Drug Discovery of GlaxoSmithKline (Psychiatry CEDD-GSK). During such period Max successfully completed is Ph.D. on the neuropsychopharmacology of cytoskeletal microtubules (University of Nottingham, UK). He then joined the French Biotech MAPREG in 2007 to establish and lead a new psychopharmacology unit. During this period he designed and successfully managed an innovative drug discovery EU granted project on microtubule-binding drugs for the treatment of depression. Transpharmation Ireland Ltd. is the only Contract Research Organization in Ireland specifically focused on psychiatric and neurodegenerative disorders currently formed by an international team of 10 people. In only a few years the company becomes a recognized world leader in the field with a global portfolio of clients including the major pharmaceutical companies. Dr. M. Bianchi is the author of several scientific publications and patents, he is also engaged to facilitate the understanding of the neurobiology of psychiatric and neurodegenerative disorders to lay people.